Biomarker ID | 1191 |
PMID | 23918943 |
Year | 2013 |
Biomarker | Methylation Status of HAPLN3 (as continous variable) |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: univariate : [HR = 1.617 (95% CI: 1.051-2.487), p-value = 0.029] |
Effect on Pathways | Pathways include: PASK human kinase ARCHS4 coexpression, PIM2 human kinase ARCHS4 coexpression, RIPK1 human kinase ARCHS4 coexpression, PRKX human kinase ARCHS4 coexpression, TESK2 human kinase ARCHS4 coexpression |
Experiment | Biochemical recurrence |
Type of Biomarker | Prognostic |
Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | 0.928 |
Accuracy | NA |
Level Of Significance | P < 0.001 |
Method Used | quantitative methylation specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | HAPLN3 |